Clinical Trial

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

Name: Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML — clinical trial record (NCT07508982)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-03

Trial Details

NCT Number	NCT07508982
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	AML
Enrollment	52 participants
Start Date	2026-05-22
Primary Completion	2029-12-12 (estimated)
Study Completion	2031-12-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-02